| Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. | |
| | |
MedLine Citation:
|
PMID: 22748936 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The interassay variability and inconsistency of plasma β-amyloid (Aβ) measurements among centers are major factors precluding the interpretation of results and a substantial obstacle in the meta-analysis across studies of this biomarker. The goal of this investigation was to address these problems by improving the performance of the bioanalytical method. METHODS: We used the Luminex immunoassay platform with a multiplex microsphere-based reagent kit from Innogenetics. A robotic pipetting system was used to perform crucial steps of the procedure. The performance of this method was evaluated using two kit control samples and two quality control plasma samples from volunteer donors, and by retesting previously assayed patient samples in each run. This setup was applied to process 2454 patient plasma samples from the Alzheimer's Disease Neuroimaging Initiative study biofluid repository. We have additionally evaluated the correlations between our results and cerebrospinal fluid (CSF) biomarker data using mixed-effects modeling. RESULTS: The average precision values of the kit controls were 8.3% for Aβ(1-40) and 4.0% for Aβ(1-42), whereas the values for the plasma quality controls were 6.4% for Aβ(1-40) and 4.8% for Aβ(1-42). From the test-retest evaluation, the average precision was 7.2% for Aβ(1-40) and 4.5% for Aβ(1-42). The range of final plasma results for Alzheimer's Disease Neuroimaging Initiative patients was 13 to 372 pg/mL (median: 164 pg/mL) for Aβ(1-40) and 3.5 to 103 pg/mL (median: 39.3 pg/mL) for Aβ(1-42). We found that sample collection parameters (blood volume and time to freeze) have a small, but significant, influence on the result. No significant difference was found between plasma Aβ levels for patients with Alzheimer's disease and healthy control subjects. We have determined multiple significant correlations of plasma Aβ(1-42) levels with CSF biomarkers. The relatively strongest, although modest, correlation was found between plasma Aβ(1-42) levels and CSF p-tau(181)/Aβ(1-42) ratio in patients with mild cognitive impairment. Plasma Aβ(1-40) correlations with CSF biomarkers were weaker and diminished completely when we used longitudinal data. No significant correlations were found for the plasma Aβ(1-42)/Aβ(1-40) ratio. CONCLUSIONS: The precision of our robotized method represents a substantial improvement over results reported in the literature. Multiple significant correlations between plasma and CSF biomarkers were found. Although these correlations are not strong enough to support the use of plasma Aβ measurement as a diagnostic screening test, plasma Aβ(1-42) levels are well suited for use as a pharmacodynamic marker. |
| | |
Authors:
|
Michal J Figurski; Teresa Waligórska; Jon Toledo; Hugo Vanderstichele; Magdalena Korecka; Virginia M Y Lee; John Q Trojanowski; Leslie M Shaw; |
Related Documents
:
|
10952466 - Role of insulin-like growth factor (igf)-1 in the modulation of renal haemodynamics in ... 3098726 - Stimulation of pig growth performance by porcine growth hormone and growth hormone-rele... 8241466 - Ngf is released into plasma during human pregnancy: an oxytocin-mediated response? 1879676 - The effect of starvation on growth and plasma growth hormone concentrations of rainbow ... 8879986 - The regulation of growth hormone secretion. 4322666 - Studies on hyperkalemic periodic paralysis. evidence of changes in plasma na and cl and... |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Alzheimer's & dementia : the journal of the Alzheimer's Association Volume: 8 ISSN: 1552-5279 ISO Abbreviation: Alzheimers Dement Publication Date: 2012 Jul |
Date Detail:
|
Created Date: 2012-07-03 Completed Date: 2012-11-13 Revised Date: 2013-04-12 |
Medline Journal Info:
|
Nlm Unique ID: 101231978 Medline TA: Alzheimers Dement Country: United States |
Other Details:
|
Languages: eng Pagination: 250-60 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Alzheimer Disease / blood*, cerebrospinal fluid, diagnosis* Amyloid beta-Peptides / blood*, cerebrospinal fluid Female Humans Immunoassay Likelihood Functions Longitudinal Studies Male Neuroimaging* Peptide Fragments / blood*, cerebrospinal fluid Statistics as Topic |
| Grant Support | |
ID/Acronym/Agency:
|
AG10124/AG/NIA NIH HHS; P30 AG010124/AG/NIA NIH HHS; U01 AG024904/AG/NIA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Amyloid beta-Peptides; 0/Peptide Fragments; 0/amyloid beta-protein (1-40); 0/amyloid beta-protein (1-42) |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The association between arterial hypertension and rotator cuff tear: the influence on rotator cuff t...
Next Document: Leptin and dementia over 32 years-The Prospective Population Study of Women.